Peng Sun

Peng Sun


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2025 in Redox Biology
Verified
Journal Article
Open access
LLLu Li
Lu Li
YCYu Cao
Yu Cao
XZXiangsheng Zhang
Xiangsheng Zhang
JGJiayi Guo
Jiayi Guo
ZLZiqiang Lin
Ziqiang Lin
SZsheng xiang zhang
sheng xiang zhang
Spinal cord injury (SCI) induced neuropathic pain (NP) remains a major clinical challenge due to persistent neuroinflammation and oxidative stress. We developed an injectable methacrylated and thiolated gelatin hydrogel loaded with quercetin (MSQ) to synergistically scavenge reactive oxygen species (ROS) and inhibit microglial ferroptosis for NP alleviation and neural repair. The MSQ hydrogel exhibited rapid photocrosslinking, sustained quercetin release, and robust ROS scavenging via thiol groups and quercetin, maintaining intracellular redox homeostasis. MSQ attenuated LPS-induced ferroptosis in BV2 microglia by upregulating Nrf2 expression, promoting its nuclear translocation, and activating the Slc7a11/Gpx4 pathway, thereby reducing lipid peroxidation and inflammatory cytokine release. Network pharmacology and molecular dynamics simulations confirmed quercetin's high-affinity binding to Nrf2. In a murine SCI model, MSQ implantation significantly reduced lesion area, suppressed microglial ferroptosis, and decreased pro-inflammatory mediators (TNFα, IL-1β, IL-6), while enhancing neuronal survival (Nissl/NeuN+ cells) and axonal regeneration (MAP2/5-HT+ expression). Motor functional recovery assays revealed improved BMS scores, gait regularity, and mechanical/thermal pain thresholds in MSQ-treated mice. This study highlights MSQ hydrogel as a multifunctional therapeutic platform that targets ROS homeostasis and microglial ferroptosis via the Nrf2/Slc7a11/Gpx4 axis, offering a promising strategy for post-SCI NP management and neural regeneration.

Verified
Journal Article
Open access
PDF file
WWwei wang
wei wang
ZLZhimin Liu
Zhimin Liu
PSPeng Sun
Peng Sun
CFCheng Fang
Cheng Fang
HFHongwei Fang
Hongwei Fang
JCJUN CHEN
JUN CHEN
Gastric cancer, a high-risk malignancy, is a genetic disease developing from a cooperation of multiple gene mutations and a multistep process. Gene therapy is a novel treatment method for treating gastric cancer. Here, we developed a novel Arg-Gly-Asp (RGD) peptides conjugated copolymers nanoparticles-based gene delivery system in order to actively targeting inhibit the growth of gastric cancer cells. These transcription factor (AP-2α) expression plasmids were also encapsulated into pluronic triblock copolymers nanoparticles which was constituted of poly(ethylene glycol)-block-poly(propylene glycol)- block-poly(ethylene glycol) (PEO-block-PPO-block-PEO, P123). The size, morphology and composition of prepared nanocomposites were further characterized by nuclear magnetic resonance (NMR), transmission electron microscopy (TEM) and dynamic light scattering (DLS). In MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) analysis, these nanocomposites have minor effects on the proliferation of GES-1 cells but significantly decreased the viability of MGC-803, suggesting they own low cytotoxicity but good antitumor activity. The following in vivo evaluation experiments confirmed that these nanocomposites could prevent the growth of gastric cancer cells in the tumor xenograft mice model. In conclusion, these unique RGD peptides conjugated P123 encapsulated AP-2α nanocomposites could selectively and continually kill gastric cancer cells by over-expression of AP-2α in vitro and in vivo; this exhibits huge promising applications in clinical gastric cancer therapy.

15 October 2025 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
PZPengyu Zhou
Pengyu Zhou
LLLu Li
Lu Li
YCYu Cao
Yu Cao
JCJiahao Chen
Jiahao Chen
CCChuyin Chen
Chuyin Chen
SZsheng xiang zhang
sheng xiang zhang
Spinal cord injury (SCI) represents a notable global health challenge, with neuropathic pain (NP) being a common complication that intensifies patient suffering. Existing research tends to overlook the temporal aspects of NP and fails to offer targeted treatment options. To tackle this issue, the present study initially examined genome‑wide association study summaries related to NP, incorporating expression quantitative trait locus (eQTL) from blood samples through summary‑based Mendelian randomization. This allowed the investigation of the association between NP and eQTL, facilitating the identification of genes linked to the risk of NP. Following this, weighted gene co‑expression network analysis of a Gene Expression Omnibus dataset was utilized to identify SCI‑related module genes, resulting in the detection of 218 shared genes across these analyses. Subsequent functional enrichment assessments, protein‑protein interaction evaluations and machine learning technique analyses, including least absolute shrinkage and selection operator regression, random forest and support vector machine recursive feature elimination analyses, highlighted three central genes: Glycerol‑3‑phosphate dehydrogenase 1‑like, epoxide hydrolase 2 and cytochrome P450 family 1 subfamily B member 1 (CYP1B1). Additionally, network pharmacology and molecular docking analyses confirmed CYP1B1 as a viable therapeutic target. A analysis of single‑cell RNA sequencing datasets demonstrated an increase in CYP1B1 expression within spinal cord fibroblasts following SCI. Furthermore, quercetin (Que) was shown to inhibit CYP1B1 expression and reduce NP (based on mechanical paw withdrawal threshold and thermal paw withdrawal latency) in murine models. The results of the present study highlight the important role of spinal cord fibroblast CYP1B1 as a notable contributor to NP following SCI and suggest that Que may serve as a promising mechanism‑based therapeutic option.

24 July 2025 in APL Bioengineering
Verified
Journal Article
Open access
XZXiangsheng Zhang
Xiangsheng Zhang
YCYu Cao
Yu Cao
LLLu Li
Lu Li
YLYike Liu
Yike Liu
PZPengyu Zhou
Pengyu Zhou
SZsheng xiang zhang
sheng xiang zhang
Spinal cord injury (SCI) severely disrupts the central nervous system, with neuropathic pain (NP) emerging as a prevalent and challenging complication, affecting approximately two-thirds of affected individuals. This study aims to explore the immune landscape and potential drug therapeutic targets associated with NP post-SCI using single-cell and bulk RNA sequencing. We identified 1050 differentially expressed genes enriched in cytokine interactions and inflammatory pathways, including key pain-related genes like Itgb2, Ccr5, Fcrg3, and Adora3, through weighted gene co-expression network analysis and immune infiltration analysis. Cell communication analysis revealed the pivotal role of the Ccl4–Ccr5 signaling axis in the interaction between macrophages and natural killer cell, thereby intensifying neuroinflammatory responses and aberrant nociceptive signaling, which may contribute to apoptosis after SCI. Molecular docking and molecular dynamics simulations showed that quercetin had stable binding with Ccr5 and identified potential amino acid binding sites TYR-108 and PHE-109. In vivo experiments demonstrated that Ccr5 inhibitors and quercetin effectively improved the Basso mouse scale and mechanical withdrawal threshold score, concurrently attenuating spinal tissue apoptosis. Therefore, we propose that quercetin and Ccr5 inhibitors could potentially treat NP post-SCI by inhibiting the Ccl4–Ccr5 pathway and reducing apoptosis, providing new treatment avenues.

1 September 2016 in British Journal of Radiology
Verified
Journal Article
Closed access
YCYi-Kan Cheng
Yi-Kan Cheng
LZLei Zeng
Lei Zeng
SYShu-Biao Ye
Shu-Biao Ye
JZJian Zheng
Jian Zheng
ZLZhang Lin
Zhang Lin
LCLei Chen
Lei Chen
To report a novel approach for craniospinal irradiation (CSI) using a supine isocentric technique. Patients were treated in the supine position using CT simulation. Half-beam blocked lateral cranial fields and superior spinal fields have the same isocenter and their beam divergences match. Tangential irradiation provides a non-divergent junction for the other two full-beam spinal fields. Shielding for cranial fields was generated and dose distribution calculated using a three-dimensional planning system. When sacral spinal fields were required, two lateral opposite fields were designed to protect the urogenital organs. All treatment portals were filmed once per week. At a median follow-up of 49.8 months, five relapses and no cases of radiation myelitis developed in 26 consecutive patients. In the junctions of the brain-spine or spine-spine field, no failure occurred. Three failures occurred in the primary site alone, 2 in the spinal axis alone. The results of our study have shown that our novel approach for CSI was not associated with increased failures at the field junction and deaths. In addition, no radiation myelitis, pneumonia, severe damage to heart and gastrointestinal tract, and second cancers occurred in our study. This new approach is an optimal alternative in cancer center without TOMO because of its convenience for immobilization, repeatability, optimal dose distribution and satisfactory clinical outcome.